Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Exelixis, Inc.NASDAQ: EXEL

Gross Margin · Q2 FY2026 · quarter ended Jul 2026

Gross margin holds steady near 96.7%

Gross margin was 96.7% in Q2 FY2026, up 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 96.5%, down 0.1 pp year over year. Over 3 fiscal years it narrowed by 0.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJul 2026
96.7%-0.0 pp QoQ
Last fiscal yearJan 2026
96.4%-0.1 pp YoY
LTMJul 2026
96.5%-0.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.1 pp——
1 year-0.1 pp——
3 years-0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
96.4%
Year-over-year change
-0.1pp

Gross Margin vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 gross margin of 96.5% is the 2nd highest of the 7 companies compared; the peer median is 92.8%.
  • Its year-over-year change of -0.1 pp is the 3rd highest of 6, against a peer median of -0.3 pp.
  • Over three fiscal years its change of -0.0 pp compares with a peer median of -1.1 pp.
EXEL Competitors Peer median
Gross Margin for EXEL and competitors
Company Period LTM level YoY 3-year change
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202698.0% -0.0 pp—
EXELExelixis, Inc.LTM Jul 202696.5% -0.1 pp-0.0 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
INCYIncyte CorporationLTM Jun 202692.6% -0.3 pp-1.1 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
HCMHUTCHMED (China) LimitedLTM Jun 20258.9% -20.9 pp+11.6 pp
RVMDRevolution Medicines, Inc.FY2025— ——
Peer median (excluding EXEL) 92.8%-0.3 pp-1.1 pp

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.43B1.61B1.83B2.17B2.32B
Cost of Revenue52.87M57.91M72.55M76.22M83.7M
Gross Profit1.38B1.55B1.76B2.09B2.24B
Gross Margin96.3%96.4%96.0%96.5%96.4%
Research & Development693.72M891.81M1.04B910.41M825M
Selling, General & Admin401.72M459.86M542.71M492.13M518.73M
Operating Expenses1.1B1.35B1.59B1.49B1.36B
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
EBITDA307.78M255.23M283.24M718.75M921.76M
EBITDA Margin21.4%15.8%15.5%33.1%39.7%
Operating Income286.67M201.48M170.89M604.62M872.19M
Operating Margin20.0%12.5%9.3%27.9%37.6%
Interest Income7.67M33.07M86.54M77.16M69.21M
Interest Expense00000
Other Income / Expenses7.49M32.87M86.64M77.02M69.02M
Income Before Tax294.15M234.35M257.52M681.64M941.21M
Pre-Tax Margin20.5%14.5%14.1%31.4%40.6%
Income Tax Expense63.09M52.07M49.76M160.37M158.64M
Net Income231.06M182.28M207.77M521.27M782.57M
Net Margin16.1%11.3%11.4%24.0%33.7%
EPS (Basic)0.730.570.651.802.88
EPS (Diluted)0.720.560.651.762.78
Weighted Avg Shares314.88M321.53M318.15M290.03M271.57M
Weighted Avg Shares (Diluted)322.36M324.56M321.46M296.13M281.86M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.